Moya-Lopez Carmen, González-Fuentes Joaquín, Bravo Iván, Chapron David, Bourson Patrice, Alonso-Moreno Carlos, Hermida-Merino Daniel
Laboratoire Matériaux Optiques Photonique et Systèmes (LMOPS), CentraleSupélec, Université de Lorraine, 57000 Metz, France.
Centro Regional de Investigaciones Biomédicas (CRIB), 02008 Albacete, Spain.
Pharmaceutics. 2022 Aug 11;14(8):1673. doi: 10.3390/pharmaceutics14081673.
The incessant developments in the pharmaceutical and biomedical fields, particularly, customised solutions for specific diseases with targeted therapeutic treatments, require the design of multicomponent materials with multifunctional capabilities. Biodegradable polymers offer a variety of tailored physicochemical properties minimising health adverse side effects at a low price and weight, which are ideal to design matrices for hybrid materials. PLAs emerge as an ideal candidate to develop novel materials as are endowed withcombined ambivalent performance parameters. The state-of-the-art of use of PLA-based materials aimed at pharmaceutical and biomedical applications is reviewed, with an emphasis on the correlation between the synthesis and the processing conditions that define the nanostructure generated, with the final performance studies typically conducted with either therapeutic agents by in vitro and/or in vivo experiments or biomedical devices.
制药和生物医学领域的不断发展,特别是针对特定疾病的定制化靶向治疗方案,需要设计具有多功能能力的多组分材料。可生物降解聚合物具有多种可定制的物理化学性质,能以低成本和低重量将健康不良副作用降至最低,是设计混合材料基质的理想选择。聚乳酸(PLA)因其具有综合的矛盾性能参数,成为开发新型材料的理想候选者。本文综述了基于PLA的材料在制药和生物医学应用方面的最新进展,重点关注合成与加工条件之间的相关性,这些条件决定了所产生的纳米结构,而最终性能研究通常通过体外和/或体内实验使用治疗剂或生物医学装置来进行。